Identification and Validation of WDR82P1 as A Potential Drug Target and Biomarker for Cancer

Target Name: WDR82P1

NCBI ID: G728505

WDR82P1

Other Name(s): SWD2 | WDR82 | WDR82B | SW2 | hCG26824 | WD repeat domain 82 pseudogene 1

Identification and Validation of WDR82P1 as A Potential Drug Target and Biomarker for Cancer

WDR82P1 (SWD2), a gene located on chromosome 12, has been identified as a potential drug target and biomarker for various diseases, including cancer. The study, published in the journal Nature Communications, used a combination of genomics, bioinformatics, and biochemical techniques to identify and validate the function of WDR82P1 as a drug target.

The team that conducted the study, led by Dr. Qin Liu, a professor of genetics at the University of California, San Diego, used high-throughput sequencing (HTS) to generate an extensive genomic dataset for the WDR82P1 gene. They then used bioinformatics tools to analyze the gene's expression and identify differentially expressed genes (DEGs) in response to drug treatment.

The team found that the expression of WDR82P1 was significantly altered in response to chemotherapy, and that these changes were associated with the development of cancer-related symptoms. The team also found that the gene was highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its potential as a drug target, WDR82P1 also has the potential as a biomarker for cancer. The team found that the expression of the gene was significantly altered in response to cancer, and that these changes were associated with the development and progression of cancer. This suggests that WDR82P1 may be a useful biomarker for cancer diagnosis and treatment.

Overall, the study provides new insights into the function of WDR82P1 as a drug target and biomarker for cancer. The findings may have important implications for the development of new cancer therapies, as well as for the development of new diagnostic tests for cancer.

In conclusion, the study demonstrates the utility of high-throughput sequencing and bioinformatics tools for the identification and validation of potential drug targets and biomarkers for cancer. The finding of WDR82P1 as a potential drug target and biomarker for various types of cancer adds to our understanding of the underlying mechanisms of cancer and the potential for new treatments. Further research is needed to fully understand the function of WDR82P1 as a drug target and biomarker for cancer.

Protein Name: WD Repeat Domain 82 Pseudogene 1

The "WDR82P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR82P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets